ixigo Partners with Uber and redBus to Integrate Cab and Bus Bookings in Train App
BASISpro Goes Live Base58Labs Rolls Out Crypto Arbitrage Trading Platform
SmallCap Biotech Stock Watch AnalystSelected Opportunities in the Emerging Therapeutics Space
Proposed Legislation Seeks YearRound E15 Ethanol Blends to Ease Gas Prices
Mercury Reaches 52 Billion Valuation Amid Fintech Recovery
Novartis Upgrades FullYear Outlook on Strong Operational Performance
Tennessee Enacts FAIR Rx Act Prohibiting PBM Ownership of Pharmacies TPA and NCPA Applaud
South Western Railway One Year After Nationalisation Progress and Reliability Questions Linger
Morrisons to Close 100 Stores Amid Rising Cost Pressures from Government Policies
Chinas Crypto Underworld Court Cases Reveal Middlemen Evading Crackdown
SCNI Q4 2023 Earnings EPS Beats Estimates Despite No Revenue
MRDN Q1 2026 Earnings Massive EPS Beat with 107647 Surprise
ResMed Q1 2026 Earnings EPS Beats Estimates but Stock Slips
IMRX Q1 2026 Earnings EPS Beat Estimates by 183 as Clinical Pipeline Advances
Prime Medicine Inc PRME Q1 2026 Earnings WiderthanExpected Loss Highlights PreRevenue Development Phase
Iron Horse Acquisitions Rights IRHOR Slips Nearly 6 as Rights Trade Near Support Levels
ADSEW Dips to 041 ADSTEC Energy Warrant Faces Resistance After Modest Decline
Neumora Therapeutics NMRA Holds Steady at 185 as Consolidation Continues
Eaton Vance Municipal Income 2028 Term Trust ETX Hovers Near Support Amid Minimal Volatility
OneConstruction Group ONEG Slips 11 Amid Sector Headwinds Key Support Test at 085
GRBK Q1 2026 Earnings Strong BottomLine Beat Despite Modest Stock Dip
ZYME Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Reports Wider Loss
BFH Q1 2026 Earnings Strong EPS Beat Amidst Stable Operations
HOVR Q1 2026 Earnings EPS Misses Estimates PreRevenue Development Continues
SDRL Q1 2026 Earnings NarrowerthanExpected Loss Boosts Surprise but Shares Slip
Marchex MCHX Q1 2026 Earnings EPS Falls Short of Consensus in Challenging Quarter
Hubbell Incorporated Draws Mixed Analyst Ratings Amid Steady Performance
YALA Q1 2026 Earnings EPS of 016 Drives 165 Stock Gain Despite Limited Data
Kazia Therapeutics KZIA Faces Sharp Decline as Biotech Volatility Resurfaces